Sucampo Acquires Vtesse Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St rebounds with broad gains as oil slides sharply
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Sucampo Pharmaceuticals (SCMP) PT Raised to $21 at Maxim Group; Vtesse 'Could Be a Great Deal'
April 3, 2017 3:20 PM EDTMaxim Group raised its price target on Sucampo Pharmaceuticals (NASDAQ: SCMP) to $21.00 (from $19.00) while maintaining a Buy rating after the company acquired privately owned Vtesse Inc. and its lead orphan drug candidate for Niemann-Pick Type C1, VTS-270, for $200 million.
Analyst Jason... More
